Myocardial revascularization in patients with acute coronary syndrome in the context of COVID-19 pandemic: a single-center prospective cohort study

Aim. To assess the outcomes of myocardial revascularization (MR) and identify risk factors for early postoperative complications in patients with coronary artery disease (CAD) with acute coronary syndrome (ACS) in the context of coronavirus disease 2019 (COVID-19) pandemic.

Material and methods. The study included 769 patients aged 67,0±4,4 years with CAD with ACS in the period from April to October 2020. In an expedited manner, percutaneous transluminal coronary angioplasty (n=699) and on pump coronary artery bypass grafting (CABG) (n=70) were performed. All patients underwent a COVID-19 rapid tests. After MR, the following outcomes were recorded: adverse cardiovascular events and other complications; various surgical interventions; bilateral COVID-19 pneumonia; death. The follow-up period lasted 30 days.

Results. During the hospitalization, COVID-19 was detected in 5,3% of patients (n=41). Among them, bilateral multisegmental pneumonia developed in 48,8%. Among infected patients, COVID-19-related mortality in the early postoperative period was 9,8%. The all-cause mortality rate was 0,7%. On pump CABG significantly increases the risk of developing COVID-19 pneumonia (odds ratio (OR), 23,2; 95% confidence interval (CI) 14,2-35,4; p<0,001). After MR, COVID-19 pneumonia was associated with respiratory (OR, 7,6; 95% CI, 4,3-11,5; p=0,001) and heart failure (OR, 4,2; 95% CI, 2,9-8,6; p=0,001), atrial fibrillation (OR, 8,3; 95% CI, 4,1-13,9; p=0,001), as well as with all-cause mortality (OR, 10,3; 95% CI, 5,2-16,7; p=0,005). Recurrent transmural myocardial infarction in patients with CAD was associated with heart failure after MR (OR, 7,1; 95% CI, 2,4-12,6; p=0,012).

Conclusion. Conducting on pump CABG in patients with CAD with ACS is the leading trigger for developing COVID-19 pneumonia, which, during hospitalization after MR, was associated not only with respiratory complications, but also with impaired heart function, which significantly increases the death risk in this category of patients.

1. Xie J, Tong Z, Guan X, et al. Clinical Characteristics of Patients Who Died of Coronavirus Disease 2019 in China. JAMA Network Open. 2020;3(4):e205619. doi:10.1001/jamanetworkopen.2020.5619.

2. Namitokov AM, Ishevskaya OP, Fetisova VI, et al. Diagnosis and treatment of acute coronary syndrome during the novel coronavirus infection covid-19 pandemic. Russ J Cardiol. 2020;25(4):3854. (In Russ.) doi:10.15829/1560-4071-2020-3854.

3. Zheng Y-Y, Ma Y-T, Zhang J-Y, et al. COVID-19 and the cardiovascular system. Nature Reviews Cardiology. 2020;17(5):259-60. doi:10.1038/s41569-020-0360-5.

4. Vereshchagin IE, Ganyukov V, Kochergin NA, et al. The results of percutaneous intervention in acute coronary syndrome depending on the type of mechanical hemodynamic support of blood circulation. Patologiya krovoobrashcheniya i kardiokhirurgiya. 2019;23(1S):34-43. (In Russ.) doi:10.21688-1681-3472-2019-1S-S34-S43.

5. Ministry of Health of Russian Federation. Temporary methodological recommendations: prevention, diagnostics and treatment of new coronavirus infection (COVID-19) v. 9 (2020 Oct 26). Russian. Available from: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/052/548/original/%D0%9C%D0%A0_COVID-19_%28v.9%29.pdf. (In Russ.)

6. Barbarash OL, Karetnikova VN, Kashtalap VV, et al. New coronavirus disease (COVID-19) and cardiovascular disease. Complex Issues of Cardiovascular Diseases. 2020;9(2):17-28. (In Russ.) doi:10.17802/2306-1278-2020-9-2-17-28.

7. Shlyakhto EV, Konradi AO, Arutyunov GP, et al. Guidelines for the diagnisis and treatment of circulatory diseases in the context of the COVID-19 pandemi. Russ J Cardiol. 2020;25(3):3801. (In Russ.) doi:10.15829/1560-4071-2020-3-3801.

8. Samsonova NN. Diagnostics and correction of hemostasis disorders in cardiac surgery. Klinicheskaya fiziologiya krovoobrashcheniya. 2018;15(2):69-74. (In Russ.) doi:10.24022/1814-6910-2018-15-2-69-74.

9. Al-Fares A, Pettenuzzo T, Del Sorbo L. Extracorporeal life support and systemic inflammation. Intensive Care Medicine Experimental. 2019;7(S1). doi:10.1186/s40635-019-0249-y.

10. Moore JB, June CH. Cytokine release syndrome in severe COVID-19. Science. 2020;368(6490):473-4. doi:10.1126/science.abb8925.

11. Xie J, Tong Zh, Guan X, et al. Critical care crisis and some recommendations during the COVID-19 epidemic in China. Intensive Care Med. 2020;46(5):837-40. doi:10.1007/s00134-020-05979-7.

12. De Luca G, Cercek M, Jensen LO, et al. Impact of COVID-19 pandemic and diabetes on mechanical reperfusion in patients with STEMI: insights from the ISACS STEMI COVID 19 Registry. Cardiovasc Diabetol. 2020;19(1):215. doi:10.1186/s12933-020-01196-0.